222 results about "Cerebral edema" patented technology

A system and related methods and components for treating a tissue site exhibiting interstitial hypertension, including tissue swelling, and particularly swelling associated with cerebral edema, compartment syndrome, and congestive heart failure, by the use of water removal therapy, in order to remove only water from biological fluids. Included also is a system for such use that incorporates one or more monitors, optionally in addition to the use of water removal therapy. By removing only water, all other biologic agents, including essentially all solutes and formed blood elements (such as cells) are increased in concentration in the remaining bodily fluid(s). WRT can be applied to several clinical conditions in which there is an excess of water, and is ideally used in an extracorporeal fashion, in combination with other functions and related components as well, including ultrafiltration.

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

The present invention is one kind of Chinese medicine composition for treating cerebral hemorrhage and is preparation process. The Chinese medicine composition consists of effective components from motherwort, giant knotweed, leech, gentian, and buffalo horn or rhinoceros horn; and may be prepared into medicine powder, tincture, capsule, tablet, micro pill and other forms. The Chinese medicine composition has the function of promoting blood circulation to disperse blood clots, and can alleviate hemorrhagic apoplexy cerebral edema, promote the absorption of hematoma and disease focus repair, improve the ischemic and anoxic state of nerve tissue around hematoma, protect damaged brain cell and promote restoring of the nerve function.

The cerebrospinal fluid (CSF) contains low concentration of albumin and insulin because of the blood-CSF barrier. This is the major reason for cerebral edema and the resultant blood perfusion deficit when brain or spinal cord is injured. A composition and method for treating brain and spinal cord are provided. The composition includes magnesium, colloidal osmotic agent, insulin and ATP in artificial CSF. The method includes withdrawing a volume of cerebrospinal fluid from the subarachnoid space and infusing the invented composition.

The invention provides an encephaledema segmentation method and system based on a support vector machine algorithm, which are applied to the medical diagnosis technology field. The encephaledema segmentation method comprises steps of using a plurality of CT images and a plurality of magnetic resonance T2 weighted images of patients suffering from first type hemorrhagic cerebral apoplexy to train a classifier based on the support vector machine algorithm, using the classifier to perform encephaledema segmentation on CT images of patients suffering from the second type hemorrhagic cerebral apoplexy, wherein the patients suffering from the first type hemorrhagic cerebral apoplexy have the CT images and the magnetic resonance T2 weighted images; and the patients suffering from the second type hemorrhagic cerebral apoplexy only have the CT images and do not have the magnetic resonance T2 weighted images. The invention utilizes few patients suffering from the hemorrhagic cerebral apoplexy having the CT images and the magnetic resonance T2 images to perform combined modeling, through studying, establishes a classifier which can identify the encephaledema on the CT from the CT image characteristics, can be applied to the patients who suffer from the hemorrhagic cerebral apoplexy and have the CT images and have no magnetic resonance T2 weighted images, and obtains the higher encephaledema segmentation accuracy.

The invention relates to an internal medicine for curing cerebral edema caused by craniocerebral injury, which pertains to traditional Chinese medicine preparation. The internal medicine of the invention is characterized in that: the effective components of the internal medicine comprises the raw pharamaceutical materials with the following parts by weight: 15-45 parts of Indian buead, 10-24 parts of polyporus, 10-24 parts of largehead atractylodes rhizome, 15-45 parts of water plaintain, 8-18 parts of twotooth achyranthes root, 15-45 parts of motherwort herb, 15-45 parts of raidx astragali, 8-18 parts of rhubarb, 8-18 parts of peach seed, 8-18 parts of rhizomaligustici chuanxiong, 10-36 parts of radix salivae miltiorrhizae, 8-18 parts of safflower, 8-18 parts of red paeony root, 10-24 parts of kudzuvine root, 8-18 parts of thinleaf milkwort root-bark and 8-18 parts of drug sweetflag rhizome. The preparation method of the internal medicine comprises the steps: all the pharamaceutical raw materials (except rhubarb) are mixed in a casserole, appropriate amount of water is added for pickling, the boiling by strong fire is firstly carried out, the rhubarb is added, the liquid medicine is filtered after half an hour, the boiling by small fire is carried out, and the liquid medicine is filtered; the two liquid medicines are mixed and cooled. The method of administration is that: the internal medicine is orally taken three times a day for conscious patients, and is injected by using a gastric tube three times a day for narcose patients. The cure rate of the composition of the invention for curing traumatic brain edema is 96%, and the effective rate is 100%.

The invention discloses a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, which is prepared from the following bulk drugs: leech, lumbricus, scorpio and pseudo-ginseng. The traditional Chinese medicine composition disclosed by the invention accords with the theories of traditional Chinese medicine pharmacology of removing stasis, promoting new and self-quenching wind through blood circulation; in addition, by utilizing the traditional Chinese medicine composition formula, the traditional Chinese medicine composition disclosed by the invention is capable of promoting circulation, removing stasis, removing blood stasis, clearing hematoma, stopping rehaemorrhagia, reducing intracranial pressure, eliminating encephaledema, adjusting whole-body blood, resisting stress reaction and improving microcirculation and has the unique curative effects to perennial serious hypertension, cerebral hemorrhage, stroke, coronary heart disease and cerebral thrombosis.

A lysine escin, its compound, production and use are disclosed. The compound consists of beta-escin lysine salt, isoescin lysine salt or their mixture and/or the other accepted carriers. It has better anti-inflammatory and anti-exudative performances, better suppressant for brain edema and medicinal safety. It can also improve blood circulation increase venous tension.

The invention relates to a Chinese traditional medicine composition for treating hydrocephalus, cerebral edema and intracranial hypertension which comprises fish encephalolith, raw astragalus root, oriental water plantain rhizome, Poria cocos, plantain seeds, notoginseng, root of red rooted saliva, sweetgum fruit, grassleaved sweetflag rhizome, evodia rutaecarpa, and achyranthes and cyathula root.

The invention relates to a brain fixed-point sub-hypothermia control device. The brain fixed-point sub-hypothermia control device comprises an intrusive guide tube, temperature detection elements, a control system, a liquid cooling device and a liquid pushing device, wherein the temperature detection elements (2, 2') are used for respectively monitoring the temperatures of an inlet and an outlet of the intrusive guide tube (1); the temperature detection element (2'') is used for monitoring the temperature of the output cooling liquid of the liquid cooling device (4); and the control system (3) is used for sending a control signal to start the liquid pushing device (5) to push the cooled liquid into the inlet of the intrusive guide tube at a certain speed. With the adoption of the brain fixed-point sub-hypothermia control device, the brain cooling part can be accurately positioned, the cooling process is timely and quick, and the sub-hypothermia state can be accurately and reliably maintained; in addition, acute and serious cerebral edema can be controlled, and conditions are created for promoting recovery of brain function, so that the brain fixed-point sub-hypothermia control device plays an important role in reducing fatality rate and disability rate.

The invention relates to the field of medical technology, which discloses a new usage of a petasites tricholobus franch extract and the contained bakkenolide compound in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases. The biological activity tests show that, the petasites tricholobus franch extract and the contained bakkenolide compound can significantly reduce the encephalic necrosis percentage of the rats with local cerebral ischemia, improve the behavior score of the ischemic rats and alleviate volume of brain edema and cerebral infarction of the rats with ischemia reperfusion injury, thus prompting that the petasites tricholobus franch extract and the contained bakkenolide compound have significant protective effect on the cerebral ischemia injury. The petasites tricholobus franch extract and the contained bakkenolide compound can further significantly reduce the J-point displacement caused by ISO and the LDH level in plasma, significantly reduce the scope of myocardial ischemic myocardial infarction of the rats caused by coronary artery ligation and lower the LDH level in the plasma of the rats with the myocardial ischemia. As the petasites tricholobus franch extract and the contained bakkenolide compound have good effects on the prevention and the treatment for heart and brain ischemic diseases aspects, the petasitestricholobus franch extract and the contained bakkenolide compound can be used in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases, including coronary heart disease, cerebral ischemia, cerebral infarction (stroke), myocardial infarction and so on.

The invention discloses injection of mannite and glycerol, which contains mannite, glycerol and water for injection. Furthermore, the invention also discloses a method for preparing the injection, which comprises the following steps: taking the mannite and the glycerol, dissolving into the water for injection, filtering and filling. The injection of the mannite and the glycerol is clinically used for treating cerebrovascular diseases, brain trauma, cerebral tumors, intracranial inflammation and the diseases of acute and chronic intracranial hypertension, hydrocephalus and the like caused by other reasons. The injection of the mannite and the glycerol has the functions of lowering the intracranial pressure quickly and eliminating the hydrocephalus and can also avoid death because of acute renal failure caused by the injury of the kidney; the injection of the mannite and the glycerol suppresses the apoptosis of neural cells and achieves the function of protecting the brain; the function of lowering the intracranial pressure is stable and has long retention time; crystals occurring because of the change of the air temperature or in the processes of storage and transportation are eliminated; and the glycerol is used as a caloric agent and can improve and recover the energy metabolism of the important viscera of the heart, the brain, the kidney and the like during oxygen deficiency. The injection of the mannite and the glycerol is a very effective, stable and safe medicine for promoting urination and removing water clinically.

The invention discloses a method for establishing a high altitude cerebral edema animal model. The method for establishing the high altitude cerebral edema animal model comprises the following steps of selecting a plurality of rats, putting the rats in a low-pressure low-oxygen environment for two days with normal diets, continuously carrying out 6 times of swimming training on the rats every day for consecutive 4-6 days, maintaining the normal diets everyday, and establishing the high altitude cerebral edema animal model, wherein a method for the swimming training comprises the steps that the rats are put into a swimming pool to swim freely, the low-pressure low-oxygen environment is maintained, the rats rest for 15-25 minutes after the rats swim for 20-30 minutes every time, and then the rats are immediately made to proceed with the swimming training of a next time. The rats can be induced to generate cerebral edema symptoms in the low-pressure low-oxygen environment; multiple times of the swimming training is carried out on the rats in several consecutive days in the low-pressure low-oxygen environment condition, the breathing frequency and the oxygen consumption of the rats are enhanced in the swimming training process, the cerebral edema symptoms of the rats are made to become obvious by increasing the oxygen consumption of the rats, and it is detected in the subsequent detection that the positive rate of cerebral edemas is increased.

We have developed a novel method of brain surface dialysis that reduces intracranial pressure and modifies movement of extracellular fluid in a rat model of brain injury. A chamber with a semipermeable membrane at the site of brain contact is perfused with a hyperosmolar solution (e.g. 15% dextran, inulin, hydroxyethyl starch). It is also capable of providing local brain cooling. In principle, osmotic forces draw water and small molecules from the injured brain into the dialysis chamber thereby reducing brain swelling. The dialysate does not move into the brain.

The invention provides an application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia. The total saponins of the bacopa monnieri (L.) wettst. mainly comprise the following dammarane type triterpenoid saponin compounds: bacopaside I, bacoside A3, bacopaside II, bacopasaponin cisomer and bacopasaponin C. The invention further provides an application of the bacopaside I in preparation of a medicament for resisting cerebral ischemia. The experimental study shows that the total saponins of the bacopa monnieri (L.) wettst. and the bacopaside I have the effects of improving the behavioral symptoms caused by cerebral ischemia reperfusion injury, reducing the cerebral infarct volume and reducing the cerebral edema caused by cerebral ischemia of a rat. Therefore, the total saponins of the bacopa monnieri (L.) wettst. can be used for preparing the medicaments for preventing and treating cerebral ischemia. The medicaments for preventing and treating the cerebral ischemia are prepared from the total saponins of the bacopa monnieri (L.) wettst. or bacopaside I as the active component and medicinal accessories by adopting a conventional method. The invention further expands the function of the bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. and provides the novel medicaments for preventing and treating the cerebral ischemia. The bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. have high clinical application values.

The invention is directed to nonpeptide substituted benzodiazepines of Formula I,

wherein A, X, n, R¹, R², R³, R⁴, R⁵, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.